Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes

Trial Profile

Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Nov 2017 Planned End Date changed from 15 May 2020 to 6 Mar 2023.
    • 17 Nov 2017 Planned primary completion date changed from 17 Aug 2018 to 10 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top